Developer docs
API playgroundTry for free, no card

Search company profiles

Microbix Biosystems

Full company profile

uuid0002eku

Namestring
Microbix Biosystems
Legal namestring
Microbix Biosystems Inc.
Websiteurl
microbix.com
Company typeenum
Public
Founded yearint
1985
Descriptiontext

Microbix Biosystems Inc. is a Canadian life-sciences company founded in 1985 and headquartered in Mississauga, Ontario, that develops biological products and technologies for the infectious disease diagnostics market. The company's core offerings fall into four buckets: (1) native viral, bacterial and parasitic antigens sold as raw materials to IVD manufacturers, vaccine R&D groups and research institutions; (2) Quality Assessment Products (QAPs) under the REDx (IVD) and PROCEEDx (RUO) brands, available as liquid and Copan FLOQSwab formulations across respiratory, HPV, STI, gastrointestinal, genital ulcer and other disease panels; (3) QUANTDx characterized, quantified reference materials used by assay developers to establish LOD, sensitivity and specificity benchmarks; and (4) the Kinlytic (urokinase) clot-dissolving biologic being modernized for sBLA re-submission with Sequel Pharma targeting a 2028 market re-entry. Supporting services include aseptic custom vial filling (up to ~60,000 vials/day on the new automated line) and diagnostic assay development support for IVD manufacturers.

The underlying technology is industrial-scale viral and bacterial culture with downstream processing, anchored in ISO 13485:2016-certified BSL-2+ facilities and complemented by in-house synthetic biology (armoured RNA, recombinant protein expression, large genetic sequence design). Microbix holds exclusive rights to manufacture external quality controls on Copan's FLOQSwabs and its products have been validated on the leading IVD platforms of Abbott (Alinity m HR HPV), BD (Onclarity HPV), Hologic (ThinPrep PreservCyt) and Seegene. Products are CE marked, FDA registered, TGA certified, UKCA marked and Health Canada licensed, and ship to more than 30 countries.

The business model is B2B, quote-based, and one-time-purchase oriented rather than subscription-based. Revenue is generated through direct sales to IVD manufacturers, clinical labs and EQA/proficiency-testing providers, complemented by a global distributor network and a contract aseptic filling service. The company serves more than 280 customers worldwide with a catalogue of 500+ products, and is publicly listed on the TSX (MBX) and OTCQX (MBXBF).

Short descriptiontext

Microbix Biosystems is a Canadian life-sciences manufacturer founded in 1985 that supplies infectious disease antigens, quality assessment products (QAPs), and characterized reference materials to IVD manufacturers, clinical laboratories, and EQA providers in 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, infectious disease antigens, quality assessment products, diagnostic reference materials, viral transport medium
Industry1 code
PRIMARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Infectious Disease Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Antigen Sales
TypeOne Time License
Description

Sale of native viral, bacterial, and parasitic antigens used as key ingredients for manufacturing diagnostic tests and external quality control materials. Antigens also serve vaccine R&D and applied research applications.

microbix.com
2Quality Assessment Products (QAPs)
TypeOne Time License
Description

Sale of external quality controls (QAPs) designed to emulate patient samples, including IVD (REDx) and RUO (PROCEEDx) product lines for quality control in diagnostic testing

microbix.com
3Reference Materials (QUANTDx)
TypeOne Time License
Description

Sale of quantified, traceable reference materials for assay development, validation, and performance benchmarking

microbix.com
4Vial Filling Services
TypeProfessional Services
Description

Aseptic custom filling services for liquids at pilot and commercial scale, accommodating various fill volumes with batch sizes up to approximately 60,000 vials

microbix.com
5Kinlytic (Urokinase)
TypeOne Time License
Description

Clot-dissolving drug being developed for market re-entry, working with Sequel Pharma and CDMO for manufacturing modernization and sBLA preparation

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1QAPs™
Description

Quality Assessment Products for external quality controls in diagnostic testing

microbix.com
+6 more records
Core offering1 text field

Microbix Biosystems develops and manufactures biological products for the infectious disease diagnostics market, producing native antigens, external quality assessment products (QAPs) under REDx and PROCEEDx brands, quantified reference materials (QUANTDx), and viral transport medium (DxTM). The company also offers aseptic custom vial filling services at pilot and commercial scales and is revitalizing Kinlytic (Urokinase), a clot-dissolving biologic drug, for market re-entry. Products are designed for IVD diagnostic manufacturers, clinical laboratories, EQA providers, and research institutions across more than 30 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Products stable at ambient temperature for two years
+3 more records
Product overview1 text field

Microbix Biosystems is a life sciences company founded in 1985, offering a portfolio of infectious disease diagnostic products and biological solutions. The core product offering comprises four main categories: (1) Antigens — native viral, bacterial, and parasitic antigens for immunoassay development, organized into panels including ToRCH, Childhood Disease, Dengue, Respiratory, STI, and Other Infectious Disease antigens; (2) External Quality Controls (QAPs) under the REDx (IVD) and PROCEEDx (RUO) brands, available as liquid and Copan FLOQSwab formulations across panels including Respiratory Viral/Bacterial, STI, HPV, Gastrointestinal, Genital Ulcer, and Vaginal Infection; (3) QUANTDx Reference Materials — quantified, traceable reference materials for assay development and validation across Fungal, Respiratory, STI, HPV, Gastrointestinal, Meningitis, and Sample Process Control panels; and (4) Kinlytic (Urokinase) — a clot-dissolving biologic drug being revitalized for market re-entry. Supporting services include Aseptic Custom Vial Filling (pilot and commercial scale up to 60,000 vials/day), Diagnostic Assay Development Services for IVD manufacturers, and ONBOARDx onboarding kits. The DxTM Viral Transport Medium and Control Elution Buffer round out the product ecosystem. The company holds ISO 13485:2016 and ISO 9001:2015 certifications and ships to 30+ countries.

Product and service8 records
1Antigens
CategoryDiagnostic Reagents
Description

One of the industry's most extensive portfolios of infectious disease antigens covering viral, bacterial, and parasitic products for diagnostic assay manufacturing, vaccine R&D, and applied research. Antigens are purified and inactivated to eliminate infectivity while maintaining antigenicity, available in panels including ToRCH, Childhood Disease, Dengue, Respiratory, STI, and Other Infectious Diseases.

2External Quality Controls (QAPs) - REDx (IVD) and PROCEEDx (RUO) brands
CategoryExternal Quality Controls
Description

Quality Assessment Products (QAPs) designed to emulate patient samples using native pathogens or synthetic genomes, available in ready-to-use liquid and swab (Copan FLOQSwab) formulations. The REDx IVD brand is CE marked for ongoing QC, operator training, and end-to-end workflow evaluation, while the PROCEEDx RUO brand supports assay verification, validation, training, and R&D applications. Products span Respiratory Viral/Bacterial, STI, HPV, Gastrointestinal, Genital Ulcer, and Vaginal Infection panels.

3QUANTDx Reference Materials
CategoryReference Materials
Description

Characterized reference materials formulated with highly concentrated, quantified, and traceable inactivated pathogens. Ideal for benchmarking assay performance during development and establishing analytical metrics such as LOD, sensitivity, and specificity. Majority quantified using digital PCR. Spans Fungal, Respiratory, STI, HPV, Gastrointestinal, Meningitis, and Sample Process Control panels.

4DxTM Viral Transport Medium
CategorySpecimen Collection Device
Description

IVD medical device designed for the secure collection and transport of specimens. Only available for sale in Canada.

5Control Elution Buffer
CategoryDiagnostic Reagents
Description

Stable sample elution buffer used as an intermediate step for preparing control swab formulations in validation/verification protocols, including the swab sample elution step.

6Kinlytic (Urokinase)
CategoryBiologic Drug Product
Description

Clot-dissolving drug (urokinase) undergoing manufacturing modernization and supplemental Biologics License Application (sBLA) preparation for market re-entry targeted in 2028, in collaboration with Sequel Pharma and a contract development organization.

7Aseptic Custom Vial Filling Services
CategoryContract Manufacturing Services
Description

Aseptic custom filling services for pilot and commercial scale, offering two production lines: a development/pilot scale line (10,000 vials per day, semi-automated, flexible) and a commercial scale line (60,000 vials per day, fully automated, includes capping and labelling). Batch sizes range from hundreds to approximately 10,000 vials.

8Diagnostic Assay Development Services
CategoryContract Development Services
Description

End-to-end solutions for IVD manufacturers supporting assay development from R&D through commercialization, including characterized raw materials, custom-developed controls (white-label), analytical and clinical validation support, assay manufacturing scale-up, and commercial launch support via ONBOARDx kits and external quality controls.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Seegene Canada
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-20
Description

Featured guest on Microbix's 'Diagnostics: Beyond the Lab' Season 2 podcast discussing diagnostic technology adoption in Canada.

stocktitan.net
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-20
Description

Featured guest on Microbix's 'Diagnostics: Beyond the Lab' Season 2 podcast discussing quality assessment for genetic testing in the UK.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-20
Description

Featured guest on Microbix's 'Diagnostics: Beyond the Lab' Season 2 podcast discussing community health outreach initiatives in Australia.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Microbix works with Sequel Pharma to advance its Kinlytic clot-dissolving drug, modernizing manufacturing methods and preparing for a supplemental biologics license application (sBLA) submission targeting market re-entry in 2028.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Microbix has been selected by CAP to supply quality assessment products (QAPs) for CAP's clinical laboratory proficiency-testing programs. Multiple SKUs of Microbix's QAPs have been provided to CAP and are now being used at subscriber clinical laboratories, with plans to expand offerings throughout fiscal 2026. CAP is the world's largest association of board-certified pathologists with approximately 20,000 members.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-03
Description

Microbix and Seegene Mexico announced a collaboration to support the clinical use of their molecular HPV detection assays through quality assessment products. The partnership aims to improve HPV screening and cervical cancer prevention efforts in Mexico and other regions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Microbix is supporting SEKISUI Diagnostics' U.S. commercialization of a COVID/Flu molecular test with its REDxFLOQ QAPs, which help ensure test accuracy and compliance. The test detects SARS-CoV-2, Influenza A, and Influenza B within 20 minutes using the Metrix platform.

Strategic tierCoreTypeTechnology or Integration
Description

Exclusive partnership where Copan's FLOQSwabs are used exclusively in Microbix's growing line of swab-formatted QAPs. Products are desiccated on FLOQSwabs for room-temperature stability and wide storage range (2-30°C).

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specializes in infectious disease antigens, inactivated viruses, and quality controls for IVD manufacturers — directly overlapping with Microbix's antigen and QAP portfolio across respiratory, STI, and ToRCH panels.

TypeDirect peer
Description

Supplies native and recombinant viral and bacterial antigens for diagnostic assay development, vaccine research, and immunoassay manufacturing — a direct competitor in the infectious disease antigen market.

3SeraCare (LGC Group)
TypeDirect peer
Description

Provides reference materials, serology QC controls, and proficiency testing materials for IVD manufacturers and clinical labs — closely comparable to Microbix's QUANTDx reference materials and QAP lines.

TypeDirect peer
Description

Develops molecular quality controls and proficiency testing samples for infectious disease assays, overlapping with Microbix's PROCEEDx RUO controls and laboratory proficiency testing panels.

TypeDirect peer
Description

Spanish manufacturer of infectious disease antigens, controls, and molecular diagnostics reagents for clinical labs and IVD manufacturers — directly comparable in size, focus, and product mix to Microbix.

TypeDirect peer
Description

Major Asian supplier of recombinant antigens, antibodies, and QC reagents for diagnostic and research use — competes with Microbix in antigen catalogs and reference materials across infectious disease panels.

TypeBroad incumbent
Description

Global life sciences leader with extensive infectious disease QC, molecular diagnostics controls, and clinical lab products — a broad incumbent whose Unity QC and molecular controls overlap with Microbix's QAPs and reference materials.

TypeBroad incumbent
Description

Large diagnostics company offering immunoassay and molecular infectious disease tests, plus associated QC controls across its Triage, Sofia, and Savanna platforms — broader portfolio than Microbix but overlapping in QC consumables.

TypeBroad incumbent
Description

Life sciences measurement and testing company that has consolidated the QC and antigen market through acquisitions of SeraCare and Native Antigen Company — a scaled incumbent competing head-to-head with Microbix.

TypeBroad incumbent
Description

Diversified life sciences tools and diagnostics company whose proteins, antibodies, and assay reagents overlap with Microbix's antigen and reference material offerings for infectious disease and immunology research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Microbix Biosystems

Infectious Disease Diagnosticsmicrobix.com

Microbix Biosystems is a Canadian life-sciences manufacturer founded in 1985 that supplies infectious disease antigens, quality assessment products (QAPs), and characterized reference materials to IVD manufacturers, clinical laboratories, and EQA providers in 30+ countries.

What Microbix Biosystems does

Microbix Biosystems Inc. is a Canadian life-sciences company founded in 1985 and headquartered in Mississauga, Ontario, that develops biological products and technologies for the infectious disease diagnostics market. The company's core offerings fall into four buckets: (1) native viral, bacterial and parasitic antigens sold as raw materials to IVD manufacturers, vaccine R&D groups and research institutions; (2) Quality Assessment Products (QAPs) under the REDx (IVD) and PROCEEDx (RUO) brands, available as liquid and Copan FLOQSwab formulations across respiratory, HPV, STI, gastrointestinal, genital ulcer and other disease panels; (3) QUANTDx characterized, quantified reference materials used by assay developers to establish LOD, sensitivity and specificity benchmarks; and (4) the Kinlytic (urokinase) clot-dissolving biologic being modernized for sBLA re-submission with Sequel Pharma targeting a 2028 market re-entry. Supporting services include aseptic custom vial filling (up to ~60,000 vials/day on the new automated line) and diagnostic assay development support for IVD manufacturers.

The underlying technology is industrial-scale viral and bacterial culture with downstream processing, anchored in ISO 13485:2016-certified BSL-2+ facilities and complemented by in-house synthetic biology (armoured RNA, recombinant protein expression, large genetic sequence design). Microbix holds exclusive rights to manufacture external quality controls on Copan's FLOQSwabs and its products have been validated on the leading IVD platforms of Abbott (Alinity m HR HPV), BD (Onclarity HPV), Hologic (ThinPrep PreservCyt) and Seegene. Products are CE marked, FDA registered, TGA certified, UKCA marked and Health Canada licensed, and ship to more than 30 countries.

The business model is B2B, quote-based, and one-time-purchase oriented rather than subscription-based. Revenue is generated through direct sales to IVD manufacturers, clinical labs and EQA/proficiency-testing providers, complemented by a global distributor network and a contract aseptic filling service. The company serves more than 280 customers worldwide with a catalogue of 500+ products, and is publicly listed on the TSX (MBX) and OTCQX (MBXBF).

Microbix Biosystems firmographics

Firmographics
Name
Microbix Biosystems
Legal name
Microbix Biosystems Inc.
Website
https://microbix.com
Company type
Public
Founded year
1985
Operating status
Operating
Headcount range
101–250 employees
Short description
Microbix Biosystems is a Canadian life-sciences manufacturer founded in 1985 that supplies infectious disease antigens, quality assessment products (QAPs), and characterized reference materials to IVD manufacturers, clinical laboratories, and EQA providers in 30+ countries.
Ownership category
akta.pro rank

Microbix Biosystems industry classification

Industry
Product category
Infectious Disease Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Keywords

  • In vitro diagnostics
  • Infectious disease antigens
  • Quality assessment products
  • Diagnostic reference materials
  • Viral transport medium

Where Microbix Biosystems is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Microbix Biosystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Antigen Sales: Sale of native viral, bacterial, and parasitic antigens used as key ingredients for manufacturing diagnostic tests and external quality control materials. Antigens also serve vaccine R&D and applied research applications.
  2. Quality Assessment Products (QAPs): Sale of external quality controls (QAPs) designed to emulate patient samples, including IVD (REDx) and RUO (PROCEEDx) product lines for quality control in diagnostic testing
  3. Reference Materials (QUANTDx): Sale of quantified, traceable reference materials for assay development, validation, and performance benchmarking
  4. Vial Filling Services: Aseptic custom filling services for liquids at pilot and commercial scale, accommodating various fill volumes with batch sizes up to approximately 60,000 vials
  5. Kinlytic (Urokinase): Clot-dissolving drug being developed for market re-entry, working with Sequel Pharma and CDMO for manufacturing modernization and sBLA preparation

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Microbix Biosystems product offering

Product offering

Core offering

Microbix Biosystems develops and manufactures biological products for the infectious disease diagnostics market, producing native antigens, external quality assessment products (QAPs) under REDx and PROCEEDx brands, quantified reference materials (QUANTDx), and viral transport medium (DxTM). The company also offers aseptic custom vial filling services at pilot and commercial scales and is revitalizing Kinlytic (Urokinase), a clot-dissolving biologic drug, for market re-entry. Products are designed for IVD diagnostic manufacturers, clinical laboratories, EQA providers, and research institutions across more than 30 countries.

Product overview

Microbix Biosystems is a life sciences company founded in 1985, offering a portfolio of infectious disease diagnostic products and biological solutions. The core product offering comprises four main categories: (1) Antigens — native viral, bacterial, and parasitic antigens for immunoassay development, organized into panels including ToRCH, Childhood Disease, Dengue, Respiratory, STI, and Other Infectious Disease antigens; (2) External Quality Controls (QAPs) under the REDx (IVD) and PROCEEDx (RUO) brands, available as liquid and Copan FLOQSwab formulations across panels including Respiratory Viral/Bacterial, STI, HPV, Gastrointestinal, Genital Ulcer, and Vaginal Infection; (3) QUANTDx Reference Materials — quantified, traceable reference materials for assay development and validation across Fungal, Respiratory, STI, HPV, Gastrointestinal, Meningitis, and Sample Process Control panels; and (4) Kinlytic (Urokinase) — a clot-dissolving biologic drug being revitalized for market re-entry. Supporting services include Aseptic Custom Vial Filling (pilot and commercial scale up to 60,000 vials/day), Diagnostic Assay Development Services for IVD manufacturers, and ONBOARDx onboarding kits. The DxTM Viral Transport Medium and Control Elution Buffer round out the product ecosystem. The company holds ISO 13485:2016 and ISO 9001:2015 certifications and ships to 30+ countries.

Differentiator

Problem solved

Functional benefit

Brands

  • QAPs™: Quality Assessment Products for external quality controls in diagnostic testing
  • QUANTDx™
  • REDx™
  • PROCEEDx™
  • ONBOARDx™
  • DxTM™
  • Kinlytic (Urokinase)

Products and services

  • Antigens One of the industry's most extensive portfolios of infectious disease antigens covering viral, bacterial, and parasitic products for diagnostic assay manufacturing, vaccine R&D, and applied research. Antigens are purified and inactivated to eliminate infectivity while maintaining antigenicity, available in panels including ToRCH, Childhood Disease, Dengue, Respiratory, STI, and Other Infectious Diseases.
  • External Quality Controls (QAPs) - REDx (IVD) and PROCEEDx (RUO) brands Quality Assessment Products (QAPs) designed to emulate patient samples using native pathogens or synthetic genomes, available in ready-to-use liquid and swab (Copan FLOQSwab) formulations. The REDx IVD brand is CE marked for ongoing QC, operator training, and end-to-end workflow evaluation, while the PROCEEDx RUO brand supports assay verification, validation, training, and R&D applications. Products span Respiratory Viral/Bacterial, STI, HPV, Gastrointestinal, Genital Ulcer, and Vaginal Infection panels.
  • QUANTDx Reference Materials Characterized reference materials formulated with highly concentrated, quantified, and traceable inactivated pathogens. Ideal for benchmarking assay performance during development and establishing analytical metrics such as LOD, sensitivity, and specificity. Majority quantified using digital PCR. Spans Fungal, Respiratory, STI, HPV, Gastrointestinal, Meningitis, and Sample Process Control panels.
  • DxTM Viral Transport Medium IVD medical device designed for the secure collection and transport of specimens. Only available for sale in Canada.
  • Control Elution Buffer Stable sample elution buffer used as an intermediate step for preparing control swab formulations in validation/verification protocols, including the swab sample elution step.
  • Kinlytic (Urokinase) Clot-dissolving drug (urokinase) undergoing manufacturing modernization and supplemental Biologics License Application (sBLA) preparation for market re-entry targeted in 2028, in collaboration with Sequel Pharma and a contract development organization.
  • Aseptic Custom Vial Filling Services Aseptic custom filling services for pilot and commercial scale, offering two production lines: a development/pilot scale line (10,000 vials per day, semi-automated, flexible) and a commercial scale line (60,000 vials per day, fully automated, includes capping and labelling). Batch sizes range from hundreds to approximately 10,000 vials.
  • Diagnostic Assay Development Services End-to-end solutions for IVD manufacturers supporting assay development from R&D through commercialization, including characterized raw materials, custom-developed controls (white-label), analytical and clinical validation support, assay manufacturing scale-up, and commercial launch support via ONBOARDx kits and external quality controls.

Quantifiable outcome

  • Products stable at ambient temperature for two years
  • +3 more outcomes

Companies that use Microbix Biosystems

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Microbix Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature5 records

Microbix Biosystems partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor, core and major.

  • Seegene CanadaminorGTM or Marketing Partner · 20 April 2026Featured guest on Microbix's 'Diagnostics: Beyond the Lab' Season 2 podcast discussing diagnostic technology adoption in Canada.
  • EMQN (UK)minorGTM or Marketing Partner · 20 April 2026Featured guest on Microbix's 'Diagnostics: Beyond the Lab' Season 2 podcast discussing quality assessment for genetic testing in the UK.
  • Kirby Institute (Australia)minorGTM or Marketing Partner · 20 April 2026Featured guest on Microbix's 'Diagnostics: Beyond the Lab' Season 2 podcast discussing community health outreach initiatives in Australia.
  • Sequel PharmacoreStrategic or Co-development Partner · 10 March 2026Microbix works with Sequel Pharma to advance its Kinlytic clot-dissolving drug, modernizing manufacturing methods and preparing for a supplemental biologics license application (sBLA) submission targeting market re-entry in 2028.
  • College of American Pathologists (CAP)coreStrategic or Co-development Partner · 10 February 2026Microbix has been selected by CAP to supply quality assessment products (QAPs) for CAP's clinical laboratory proficiency-testing programs. Multiple SKUs of Microbix's QAPs have been provided to CAP and are now being used at subscriber clinical laboratories, with plans to expand offerings throughout fiscal 2026. CAP is the world's largest association of board-certified pathologists with approximately 20,000 members.
  • Seegene MexicomajorStrategic or Co-development Partner · 3 December 2025Microbix and Seegene Mexico announced a collaboration to support the clinical use of their molecular HPV detection assays through quality assessment products. The partnership aims to improve HPV screening and cervical cancer prevention efforts in Mexico and other regions.
  • SEKISUI DiagnosticscoreStrategic or Co-development Partner · 12 November 2025Microbix is supporting SEKISUI Diagnostics' U.S. commercialization of a COVID/Flu molecular test with its REDxFLOQ QAPs, which help ensure test accuracy and compliance. The test detects SARS-CoV-2, Influenza A, and Influenza B within 20 minutes using the Metrix platform.
  • CopancoreTechnology or IntegrationExclusive partnership where Copan's FLOQSwabs are used exclusively in Microbix's growing line of swab-formatted QAPs. Products are desiccated on FLOQSwabs for room-temperature stability and wide storage range (2-30°C).

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Microbix Biosystems competitors and assessment

Company assessment

Direct peers

  • ZeptoMetrix (Antylia Scientific): Specializes in infectious disease antigens, inactivated viruses, and quality controls for IVD manufacturers — directly overlapping with Microbix's antigen and QAP portfolio across respiratory, STI, and ToRCH panels.
  • The Native Antigen Company (LGC Group): Supplies native and recombinant viral and bacterial antigens for diagnostic assay development, vaccine research, and immunoassay manufacturing — a direct competitor in the infectious disease antigen market.
  • SeraCare (LGC Group): Provides reference materials, serology QC controls, and proficiency testing materials for IVD manufacturers and clinical labs — closely comparable to Microbix's QUANTDx reference materials and QAP lines.
  • Maine Molecular Quality Controls (MMQC): Develops molecular quality controls and proficiency testing samples for infectious disease assays, overlapping with Microbix's PROCEEDx RUO controls and laboratory proficiency testing panels.
  • Vircell: Spanish manufacturer of infectious disease antigens, controls, and molecular diagnostics reagents for clinical labs and IVD manufacturers — directly comparable in size, focus, and product mix to Microbix.
  • Sino Biological: Major Asian supplier of recombinant antigens, antibodies, and QC reagents for diagnostic and research use — competes with Microbix in antigen catalogs and reference materials across infectious disease panels.

Broad incumbents

  • Bio-Rad Laboratories: Global life sciences leader with extensive infectious disease QC, molecular diagnostics controls, and clinical lab products — a broad incumbent whose Unity QC and molecular controls overlap with Microbix's QAPs and reference materials.
  • QuidelOrtho: Large diagnostics company offering immunoassay and molecular infectious disease tests, plus associated QC controls across its Triage, Sofia, and Savanna platforms — broader portfolio than Microbix but overlapping in QC consumables.
  • LGC Group: Life sciences measurement and testing company that has consolidated the QC and antigen market through acquisitions of SeraCare and Native Antigen Company — a scaled incumbent competing head-to-head with Microbix.
  • Bio-Techne: Diversified life sciences tools and diagnostics company whose proteins, antibodies, and assay reagents overlap with Microbix's antigen and reference material offerings for infectious disease and immunology research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Microbix Biosystems social profiles

Digital presence

Microbix Biosystems compliance and trust

Trust signal

Compliance9 records

Microbix Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Microbix Biosystems leadership team

Management profile

Number of profiles

Profiles3 records

Microbix Biosystems funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Microbix Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microbix Biosystems

What does Microbix Biosystems do?

Microbix Biosystems develops and manufactures biological products for the infectious disease diagnostics market, producing native antigens, external quality assessment products (QAPs) under REDx and PROCEEDx brands, quantified reference materials (QUANTDx), and viral transport medium (DxTM). The company also offers aseptic custom vial filling services at pilot and commercial scales and is revitalizing Kinlytic (Urokinase), a clot-dissolving biologic drug, for market re-entry. Products are designed for IVD diagnostic manufacturers, clinical laboratories, EQA providers, and research institutions across more than 30 countries.

Is Microbix Biosystems a public or private company?

Microbix Biosystems is a public company. It is classified as public and is currently operating.

When was Microbix Biosystems founded?

Microbix Biosystems was founded in 1985. It employs 101 to 250 people.

Where is Microbix Biosystems based?

Microbix Biosystems is headquartered in Toronto, Canada, in the North America region.

How does Microbix Biosystems make money?

Five revenue lines are on record. Antigen Sales are the primary driver. The others are quality Assessment Products (QAPs), reference Materials (QUANTDx), vial Filling Services and kinlytic (Urokinase).

Who are Microbix Biosystems's main competitors?

Direct peers on record are ZeptoMetrix (Antylia Scientific), The Native Antigen Company (LGC Group), SeraCare (LGC Group), Maine Molecular Quality Controls (MMQC), Vircell and Sino Biological. Broad incumbents are Bio-Rad Laboratories, QuidelOrtho, LGC Group and Bio-Techne.

Does Microbix Biosystems have an API?

No public API is recorded for Microbix Biosystems.

What industry is Microbix Biosystems in?

Microbix Biosystems's product category is Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanMicrobix starts sales of custom assay controls to 2 test firmsMicrobix Biosystems announced it has commercialized custom biologic materials for sample-processing controls in in-vitro diagnostics assays, with initial sales to two DxMs. The materials support DNA and RNA-based assays, including reverse-transcription steps, and Microbix expects recurring sales and additional clients.Stock TitanMicrobix to Give Masters Summit Keynote Oct. 12-15Microbix Biosystems will present a keynote at MasterControl's Masters Summit 2026 in Salt Lake City, Oct. 12-15, with two executives sharing its eQMS adoption experience. The company selected MasterControl eQMS in 2022, and it now supports its operational, R&D, manufacturing, QC, and QA functions.YahooMicrobix Biosystems Inc (MBXBF) (Q3 2026) Earnings Call Highlights: Revenue Surges 17% as Gross ...Microbix Biosystems Inc reported a 17% year-over-year revenue increase for Q3 fiscal 2026, driven by a 20% rise in antigen sales and improved gross margins reaching 54%. The company continues to incur net losses despite strict cost controls and is actively repurchasing shares while advancing its Kinlytic therapeutic program. However, the firm faces ongoing challenges including reliance on a few large clients, delayed agreements with international partners, and stagnant sales in China.Markets DailyMicrobix Biosystems (TSE:MBX) Posts Quarterly Earnings ResultsMicrobix Biosystems reported a quarterly loss of C$0.01 per share with revenue of C$4.06 million, while highlighting a 17% year-over-year increase in Q3 revenue and improved gross margins. The company anticipates continued growth toward break-even in Q4 and is progressing Kinlytic development toward an FDA meeting and a supplemental BLA filing in 2027. Management also noted ongoing discussions with major international diagnostics companies for potential material projects.Seeking AlphaMicrobix Biosystems Inc. (MBX:CA) Q3 2026 Earnings Call TranscriptMicrobix Biosystems Inc. reported its Q3 2026 financial results, which the company described as showing progress in its business operations. The earnings call featured an overview of the quarter's performance followed by a question-and-answer session with executives.Investing.comEarnings call transcript: Microbix posts 17% Q3 sales growth in 2026 By Investing.comMicrobix reported a 17% year-over-year increase in third-quarter fiscal 2026 revenue, driven by stronger sales in its antigen and quality assurance product lines, while gross margins expanded significantly to 54%. The company is progressing toward its engineered break-even point and expects continued growth in the fourth quarter, alongside regulatory advancements for its Kinlytic therapeutic asset. Management highlighted improved manufacturing efficiencies and diversification into direct laboratory sales as key factors supporting the recovery from previous client setbacks.YahooMicrobix Reports Results for Q3 Fiscal 2026Microbix Biosystems Inc. reported Q3 fiscal 2026 revenues of $4.1 million, marking a 17% increase from the previous year and signaling continued recovery from prior client setbacks. The company also achieved an improved gross margin of 54% and reduced its net loss to $806,762 compared to $1.64 million in the same period last year.